BRENTUXIMAB VEDOTIN

Brentuximab vedotin is an antibodydrug conjugate targeting CD30expressing cells, delivering a cytotoxic payload. Used in Hodgkin lymphoma and ALCL, it improves remission rates. Side effects include neuropathy, neutropenia, infections, and infusion reactions. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 448e0e9c077e Category: Tag:

Product Description


Mechanism of action

Brentuximab vedotin is an antibodydrug conjugate (ADC) composed of an antiCD30 monoclonal antibody linked to monomethyl auristatin E (MMAE). After CD30 binding, the ADC is internalised and MMAE is released, disrupting microtubule formation, triggering G/M cellcycle arrest and inducing apoptosis.

Benefits and advantages

Critical in targetedtherapy research, lymphoma biology, ADCmechanism modelling, microtubuledisruption studies, tumourselective drugdelivery investigations and immunooncology development.

Side effects and risks

Risks include peripheral neuropathy, neutropenia, infusion reactions, hepatotoxicity and serious infections. Handle under biologic/cytotoxic dualcontainment requirements.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Weight

g/mol

CAS Number

914088-09-8

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

IUPAC/Chemical Name

Antibodydrug conjugate (anti€‘CD30 monoclonal antibody + MMAE)

References

https://pubchem.ncbi.nlm.nih.gov/#query=914088-09-8;

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download